
FTC Challenge Forces Sanofi to Terminate $750M Maze Therapeutics Deal
Sanofi expresses disappointment with the Federal Trade Commission's decision to seek a preliminary injunction against its proposed licensing agreement with Maze Therapeutics for the development of MZE001, a potential treatment for Pompe Disease. Sanofi disagrees with the action, stating that it would delay potential advancements and impact patients' lives. As a result, Sanofi has decided to terminate the agreement with Maze Therapeutics. The company remains committed to addressing the unmet needs of the Pompe patient community.

